{"slug":"gist","tag":"gist","variants":["gist"],"description":"No description yet","count":5,"kinds":{"person":4,"biomarker":1},"related":[{"slug":"trialist","tag":"trialist","shared":3},{"slug":"sarcoma","tag":"sarcoma","shared":2},{"slug":"targeted-therapy","tag":"targeted-therapy","shared":2},{"slug":"biomarker","tag":"biomarker","shared":1}],"records":[{"id":"george-demetri","kind":"person","name":"George D. Demetri","route":"/people/george-demetri/","tldr":"Led the imatinib trial in GIST that proved a targeted drug could melt away a solid tumour, and every GIST kinase inhibitor since."},{"id":"michael-heinrich","kind":"person","name":"Michael C. Heinrich","route":"/people/michael-heinrich/","tldr":"Oregon physician-scientist who showed that the KIT mutation type in a GIST predicts how well imatinib works, discovered PDGFRA mutations in the tumours without KIT mutations, and led NAVIGATOR, which established avapritinib for PDGFRA D842V disease."},{"id":"sebastian-bauer","kind":"person","name":"Sebastian Bauer","route":"/people/sebastian-bauer/","tldr":"German sarcoma specialist who was lead author of INTRIGUE, the trial that compared ripretinib with sunitinib as second-line treatment for GIST."},{"id":"heikki-joensuu","kind":"person","name":"Heikki Joensuu","route":"/people/heikki-joensuu/","tldr":"Finnish oncologist who treated the first GIST patient with imatinib in 2000 and led SSG XVIII, the trial that showed three years of adjuvant imatinib beats one year after surgery for high-risk GIST."},{"id":"pdgfra-exon-18-d842v","kind":"biomarker","name":"PDGFRA exon 18 mutation (D842V)","route":"/biomarkers/pdgfra-exon-18-d842v/","tldr":"PDGFRA D842V drives about 5 percent of gastrointestinal stromal tumours and is resistant to imatinib. Avapritinib is the approved drug for GISTs with PDGFRA exon 18 mutations including D842V."}]}